277 related articles for article (PubMed ID: 18584174)
1. Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ and CD8+ T cell epitopes.
Bettahi I; Dasgupta G; Renaudet O; Chentoufi AA; Zhang X; Carpenter D; Yoon S; Dumy P; BenMohamed L
Cancer Immunol Immunother; 2009 Feb; 58(2):187-200. PubMed ID: 18584174
[TBL] [Abstract][Full Text] [Related]
2. Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity.
Renaudet O; Dasgupta G; Bettahi I; Shi A; Nesburn AB; Dumy P; BenMohamed L
PLoS One; 2010 Jun; 5(6):e11216. PubMed ID: 20574522
[TBL] [Abstract][Full Text] [Related]
3. Both CD4+ and CD8+ T cell epitopes fused to heat shock cognate protein 70 (hsc70) can function to eradicate tumors.
Mizukami S; Kajiwara C; Ishikawa H; Katayama I; Yui K; Udono H
Cancer Sci; 2008 May; 99(5):1008-15. PubMed ID: 18341654
[TBL] [Abstract][Full Text] [Related]
4. Branched and linear lipopeptide vaccines have different effects on primary CD4+ and CD8+ T-cell activation but induce similar tumor-protective memory CD8+ T-cell responses.
Baz A; Buttigieg K; Zeng W; Rizkalla M; Jackson DC; Groves P; Kelso A
Vaccine; 2008 May; 26(21):2570-9. PubMed ID: 18420312
[TBL] [Abstract][Full Text] [Related]
5. Induction of homologous rather than heterologous antigen-specific CD4 T cell responses is critical for functional CD8 T cell responses in mice transgenic for a foreign antigen.
Sabarth N; Chamberlain L; Brett S; Tite J; Craigen J
J Immunol; 2010 Oct; 185(8):4590-601. PubMed ID: 20861346
[TBL] [Abstract][Full Text] [Related]
6. Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-γ and reduces parasite burden in HLA-B*0702 mice.
Cong H; Mui EJ; Witola WH; Sidney J; Alexander J; Sette A; Maewal A; El Bissati K; Zhou Y; Suzuki Y; Lee D; Woods S; Sommerville C; Henriquez FL; Roberts CW; McLeod R
Hum Immunol; 2012 Jan; 73(1):1-10. PubMed ID: 22027386
[TBL] [Abstract][Full Text] [Related]
7. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines.
Bettahi I; Nesburn AB; Yoon S; Zhang X; Mohebbi A; Sue V; Vanderberg A; Wechsler SL; BenMohamed L
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4643-53. PubMed ID: 17898288
[TBL] [Abstract][Full Text] [Related]
8. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
[TBL] [Abstract][Full Text] [Related]
9. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
[TBL] [Abstract][Full Text] [Related]
10. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
Rowe HM; Lopes L; Ikeda Y; Bailey R; Barde I; Zenke M; Chain BM; Collins MK
Mol Ther; 2006 Feb; 13(2):310-9. PubMed ID: 16275163
[TBL] [Abstract][Full Text] [Related]
11. The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustion.
Zhang Y; Ertl HC
J Immunol; 2014 Aug; 193(4):1836-46. PubMed ID: 25024391
[TBL] [Abstract][Full Text] [Related]
12. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of a recombinant influenza virus bearing both the CD4+ and CD8+ T cell epitopes of ovalbumin.
Garulli B; Di Mario G; Sciaraffia E; Kawaoka Y; Castrucci MR
J Biomed Biotechnol; 2011; 2011():497364. PubMed ID: 22007143
[TBL] [Abstract][Full Text] [Related]
14. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
[TBL] [Abstract][Full Text] [Related]
15. Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help.
Krishnan L; Sad S; Patel GB; Sprott GD
J Immunol; 2000 Nov; 165(9):5177-85. PubMed ID: 11046050
[TBL] [Abstract][Full Text] [Related]
16. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
17. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
18. Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy.
Snook AE; Magee MS; Schulz S; Waldman SA
Eur J Immunol; 2014 Jul; 44(7):1956-66. PubMed ID: 24771148
[TBL] [Abstract][Full Text] [Related]
19. A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling.
Xie Y; Wang L; Freywald A; Qureshi M; Chen Y; Xiang J
Cell Mol Immunol; 2013 Jan; 10(1):72-7. PubMed ID: 23042534
[TBL] [Abstract][Full Text] [Related]
20. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
Yang Y; Che Y; Zhao Y; Wang X
Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
